Therapeutic Potential of Aceh's Syzygium polyanthum in Reducing Uric Acid in Rattus Norvegicus
Malacca Pharmaceutics · 2024
DOI: 10.60084/mp.v2i2.210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Malacca Pharmaceutics, 2024. Verfasst von Nasrullah Nasrullah und 2 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This research aims to evaluate the anti-hyperuricemic activity of Syzygium polyanthum ethanolic extract in hyperuricemic male rats (Rattus norvegicus) induced by liver juice. A total of 25 animals were divided into five groups: a negative control group, a positive control group, and three treatment groups receiving S. polyanthum extract at doses of 150, 200, and 250 mg/kg body weight, respectively. The result showed that the dose of 250 mg/kg body weight resulted in the highest decrease of uric acid plasma, measuring 3.44 ± 2.03 mg/dL. This reduction is comparable to the effect of allopurinol, which showed a decrease of 3.70 ± 1.54 mg/dL. A minimum dose-dependent activity was observed. To conclude, the administration of ethanolic extract of S. polyanthum for 14 days significantly reduced uric acid levels. Further exploration of higher doses or a long-term treatment period to enhance its effectiveness is needed.
Zitieren
APA
Nasrullah, N., Siregar, M. L., & Suryawati, S. (2024). Therapeutic Potential of Aceh's Syzygium polyanthum in Reducing Uric Acid in Rattus Norvegicus. Malacca Pharmaceutics. https://doi.org/10.60084/mp.v2i2.210
Vancouver
Nasrullah N, Siregar ML, Suryawati S. Therapeutic Potential of Aceh's Syzygium polyanthum in Reducing Uric Acid in Rattus Norvegicus. Malacca Pharmaceutics. 2024. doi:10.60084/mp.v2i2.210
BibTeX
@article{Nasrullah2024,
author = {Nasrullah, Nasrullah and Siregar, Masra Lena and Suryawati, Suryawati},
title = {Therapeutic Potential of Aceh's Syzygium polyanthum in Reducing Uric Acid in Rattus Norvegicus},
journal = {Malacca Pharmaceutics},
year = {2024},
doi = {10.60084/mp.v2i2.210}
}
EUVIMED